NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Corcept Therapeutics Incorporated (CORT) Stock Analysis

Corcept Therapeutics Incorporated (CORT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CORT

$116.28

−$0.17 (−0.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CORT with… →

CORT Key Statistics

As of Oct 21, 2026
Trading
Open
$116.45
Previous Close
$116.45
Day's Range
116.13–118.41
52-Week Range
28.66–126.38
Volume
516.75K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.40
Valuation
Market Cap
$12.57B
P/E Ratio
258.40
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
26.40
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
15.13
EPS (ttm)Profit attributable to each share over the last twelve months.
0.45
Financials (FY)
Revenue (FY)
$761.41M+12.79%
Net Income (FY)
$99.65M−29.43%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
108.10M
1-Year Return
+54.24%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.21M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CORT closed at $116.28, +54.24% over 1 year.

Corcept Therapeutics Incorporated (CORT) has a market capitalization of $12.57B.

In fiscal 2025, CORT reported revenue of $761.41M.

CORT Stock Return by Calendar Year

Corcept Therapeutics Incorporated (CORT) 10-year return: what $10,000 became

1 year
$10,000 $15,424
+54.24%
5 years
$10,000 $61,818
+518.18%
10 years
$10,000 $167,550
+1,575.50%

If you had invested $10,000 in Corcept Therapeutics Incorporated (CORT) 10 years ago, at the close on October 21, 2016, it would have been worth $167,550 at the close on October 21, 2026: +1,575.50% in total, +32.56% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+234.14%
2025−30.94%
2024+55.14%
2023+59.92%
2022+2.58%
2021−24.31%
2020+116.20%
2019−9.43%
2018−26.02%
2017+148.76%
2016 (partial year)+24.53%

As of October 21, 2026.

CORT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$761.41M$99.65M13.1%
2024$675.04M$141.21M20.9%
2023$482.38M$106.14M22.0%
2022$401.86M$101.42M25.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$761.41M$748.43M$44.80M$99.65M13.1%
2024$675.04M$664.16M$136.95M$141.21M20.9%
2023$482.38M$475.89M$107.28M$106.14M22.0%
2022$401.86M$396.47M$112.63M$101.42M25.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CORT Valuation vs Biotechnology Median

Median of 608 stocks
MetricCORTBiotechnology medianvs median
P/E258.4016.6015.6x the median
P/S ratio15.1313.3014% above
Profit margin6.64%−38.31%45.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Corcept Therapeutics Incorporated (CORT) carries a market capitalisation of $12.57B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 730.

The 52-week range on file runs from $28.66 to $126.38. CORT last closed at $116.28 on October 21, 2026. That is −$0.17 (−0.15%) against the previous close. The latest close sits 305.72% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $761.41M. Against the prior fiscal year total of $675.04M, that is a change of +12.79%. The same year closed with net income of $99.65M. That is −29.43% against the prior fiscal year. The reported profit margin is 6.64%. That is 45 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 0.45.

Across the 4 fiscal years on file, revenue moves from $401.86M in 2022 to $761.41M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 258.4. That is 15.6 times the Biotechnology median of 16.6. The forward P/E on file is 26.4. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.81. Measured against sales, the shares trade at 15.13 times revenue. On price-to-sales that is 13.77% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +54.24%. Across 10 years the annualized return works out at +32.56%. Beta against the wider market is reported at 0.4. Daily returns over the trailing 10 years annualize to a volatility of 67.79%.

Growth & Income

The record shows no dividend for CORT.

So far in 2026 the total return is +234.14%. Across the complete calendar years on file, 2017 returned +148.76% and 2025 returned −30.94%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Corcept Therapeutics Incorporated (CORT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Corcept Therapeutics Incorporated CORT $12.57B 258.4
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Corcept Therapeutics Incorporated trades at a P/E of 258.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Visit website →